Champions Oncology's Core Services Surge 32% in Q3, Total Revenue Dips on One-Time Item
summarizeSummary
Champions Oncology reported a 3% dip in fiscal Q3 revenue to $16.60 million. This decline was primarily attributed to the absence of a $4.5 million data license revenue recognized in the prior-year period. Crucially, the company's core study service revenue achieved a record high, increasing 32% year-over-year due to strong study execution and backlog conversion. The company also reported positive adjusted EPS of $0.04 and maintains a positive outlook, expecting year-over-year revenue growth and positive adjusted EBITDA for the full fiscal year. This indicates robust underlying business performance despite the top-line dip from a non-recurring item, providing a more optimistic view than the headline initially suggests. Investors will be watching for continued growth in study service revenue and the company's progress towards its full fiscal year guidance.
At the time of this announcement, CSBR was trading at $5.74 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $79.7M. The 52-week trading range was $5.59 to $10.25. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.